Monopar Therapeutics (MNPR) Corporate presentation summary

Company overview and leadership

• Clinical-stage biopharma focused on ALXN1840 for Wilson disease and MNPR-101 for oncology, with experienced leadership in drug development and commercialization.

• Executive team includes co-founders of BioMarin, Raptor Pharma, and Tactic Pharma, with proven track records in rare disease and oncology drug launches.

Pipeline and clinical milestones

• ALXN1840 completed Phase 3 for Wilson disease, meeting primary endpoint; NDA filing targeted for mid-2026.

• MNPR-101 is in Phase 1 trials for aggressive cancers, with active recruitment for imaging and therapeutic studies.

• ALXN1840 has Orphan Drug and Fast Track designations in the US and orphan designation in the EU.

Wilson disease: unmet need and ALXN1840 mechanism

• Wilson disease is a rare genetic disorder causing toxic copper accumulation, leading to severe hepatic and neurological symptoms.

• Current standard of care is outdated, with suboptimal efficacy and high discontinuation rates.

• ALXN1840 is a first-in-class albumin tripartite complex activator that sequesters copper, preventing toxic accumulation.